Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Ligand Reports Second Quarter 2022 Financial Results
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Ligand to Report Second Quarter Financial Results on August 8
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Ligand Reports First Quarter 2022 Financial Results
Ligand to Report First Quarter Financial Results on May 4
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Ligand to Report Fourth Quarter Financial Results on February 17
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
